Analysts Set Envista Holdings Co. (NYSE:NVST) PT at $20.21

Envista Holdings Co. (NYSE:NVST) has earned a consensus recommendation of “Hold” from the fourteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $20.21.

A number of analysts recently weighed in on the stock. Wells Fargo & Company increased their price objective on shares of Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a report on Thursday, February 6th. Robert W. Baird increased their price objective on shares of Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Leerink Partnrs raised shares of Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a report on Thursday, February 6th. Finally, Jefferies Financial Group increased their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd.

Hedge Funds Weigh In On Envista

Several large investors have recently bought and sold shares of the stock. Ariel Investments LLC increased its stake in Envista by 6.2% during the 4th quarter. Ariel Investments LLC now owns 12,059,624 shares of the company’s stock valued at $232,630,000 after buying an additional 699,625 shares during the period. Nuance Investments LLC boosted its position in shares of Envista by 4.4% during the 3rd quarter. Nuance Investments LLC now owns 7,346,534 shares of the company’s stock valued at $145,168,000 after purchasing an additional 308,221 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Envista by 72.6% during the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company’s stock valued at $132,223,000 after purchasing an additional 2,882,844 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Envista by 19.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company’s stock valued at $130,440,000 after purchasing an additional 1,089,923 shares in the last quarter. Finally, Gates Capital Management Inc. boosted its position in shares of Envista by 15.1% during the 4th quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company’s stock valued at $90,550,000 after purchasing an additional 615,577 shares in the last quarter.

Envista Trading Up 2.4 %

Envista stock opened at $21.36 on Tuesday. The firm’s 50-day moving average is $20.15 and its 200-day moving average is $19.59. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. Envista has a 1 year low of $15.15 and a 1 year high of $23.00. The company has a market cap of $3.68 billion, a P/E ratio of -3.29, a PEG ratio of 1.27 and a beta of 1.34.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. On average, equities analysts expect that Envista will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.